ANRO (Alto Neuroscience) Other Stockholders Equity: $0.00 Mil (As of Mar. 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $26.06
! 2 Warning Signs
View Full Analysis

What is Alto Neuroscience Other Stockholders Equity?

Alto Neuroscience ANRO -1.25% 12 Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Alto Neuroscience's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

Alto Neuroscience's quarterly Other Stockholders Equity increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Alto Neuroscience's annual Other Stockholders Equity stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Alto Neuroscience Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience Other Stockholders Equity Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
0.00 0.00 0.00 0.00 0.00

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ANRO
12GF Score
Alto Neuroscience Inc ANRO
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Alto Neuroscience (ANRO) has a Other Stockholders Equity of $0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Alto Neuroscience and its competitors.
Is Alto Neuroscience's Other Stockholders Equity too high?
Alto Neuroscience's current Other Stockholders Equity is $0.00 Mil. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Other Stockholders Equity compare to SANA and AVTX?
Alto Neuroscience's Other Stockholders Equity of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Alto Neuroscience and its competitors. Alto Neuroscience's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Other Stockholders Equity of $0.00 Mil. The current Other Stockholders Equity is $0.00 Mil. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.06
Price